Q2 FY27 revenue hits record Rs 697.6 crore; margin improvement planned

Mgmt Guided Margin ImprovementCfo Debt Reduction RoadmapInvestor Communications View source PDF Explain this filing

ROSSARI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.3%Reaction day

₹429.00

prior close

₹424.35

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.3%-0.9% vs market

Specialty Chemicals peers, median of 100sector-3.3%+0.1% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 0.1 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.9

10m

-3.0

15m

-3.2

30m

-4.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.3-2.3-0.9-3.3+0.1

Next day

-5.2-1.9-3.3-3.4-1.8

-5.1-0.2-4.8-1.4-3.6

-4.2pendingpending-1.4-2.9

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 100Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Rossari Biotech reported record Q2 FY27 revenue of Rs 697.6 crore, up 19 percent year on year, and EBITDA of Rs 87 crore, up 21 percent. Gross margin was 31.6 percent and EBITDA margin 12.5 percent. Management plans margin improvement through cost control, better product mix and exiting low-margin businesses. Net debt fell to Rs 221 crore in H1, with debt reduction remaining the first use of cash.

Likely market impact

Record growth and lower debt are positive, but freight costs and planned Saudi investment may limit near-term earnings and cash flow gains.